Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.
Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.
A difference is not always a contradiction
Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.
ONUREG: oral renal instructions are not injectable azacitidine dosing
Oral no-adjustment guidance coexists with intensified severe-renal monitoring and incomplete oral PK evidence.
What to reconcile
Retain the toxicity-monitoring qualification; do not substitute the injectable regimen.
1 source identities and dates
GlobalRPh RX List - ONUREG
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Azacitidine - ONUREG oral tablets; selected source sections only, not a complete prescribing monograph.
The inhaled-product renal statement must not overwrite systemic aztreonam
The mirror qualifies its no-adjustment wording by low systemic exposure and limited trial renal coverage.
What to reconcile
Confirm inhaled CAYSTON rather than IV aztreonam or a fixed combination.
1 source identities and dates
GlobalRPh RX List - CAYSTON
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. CAYSTON aztreonam for inhalation solution in cystic fibrosis; not systemic aztreonam or aztreonam/avibactam.
Qualitative caution is not permission for standard dosing
The selected renal paragraph warns about reduced elimination but supplies no clearance-based schedule.
What to reconcile
Assess CNS toxicity and advanced-renal risk. The separate oral baclofen record has additional attributed literature; it is not an intrathecal substitute.
1 source identities and dates
GlobalRPh RX List - LYVISPAH
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. LYVISPAH oral granules, including its labeled enteral administration options. Not intrathecal baclofen.
Baclofen: qualitative label caution versus case-based avoidance guidance
The OZOBAX label gives no numerical cutoff. Wolf et al. recommend reduction in moderate dysfunction and avoidance in severe dysfunction or renal replacement therapy, based on case-based expert interpretation.
What to reconcile
Attribute the literature recommendation and evidence limits. Do not invent a reduction percentage or describe it as a product-specific trial.
2 source identities and dates
GlobalRPh RX List - OZOBAX
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Baclofen - OZOBAX oral solution; selected source sections only, not a complete prescribing monograph.
Older-adult avoidance guidance is more conservative than a generic reduction instruction
AGS 2023 recommends avoidance in older adults below its eGFR threshold, whereas the product-label summary advises caution and possible reduction.
What to reconcile
Review the age-specific source before using a reduced-dose schedule. The geriatric warning is not an intrathecal dosing rule.
2 source identities and dates
Baclofen oral immediate-release tablets - selected U.S. labeling
U.S. product labeling / DailyMed | Source revision: Label revision date not separately recorded; retrieval date is not the revision date. Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
American Geriatrics Society expert panel | Source revision: 2023 AGS Beers Criteria, published May 4, 2023 Adults aged 65 years and older receiving oral baclofen; not intrathecal therapy.
GlobalRPh-hosted RX List | Source revision: Revision date not established in selected retrieval. IV belinostat; older RX List renal statement. Compare with the separately presented newer label.
Current renal paragraphs agree; preserve the dated disagreement
The September 2026 RX retrieval now matches the official renal section. The older saved mirror gap remains historical, not the current retrieved wording.
What to reconcile
Read the new sources first. A separate UGT1A1-inhibitor rule matters at the reduced dose; concordance is not full clinical approval.
2 source identities and dates
GlobalRPh RX List - BELEODAQ
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. BELEODAQ IV; selected renal sections rechecked in September 2026. Earlier source snapshots remain separately visible.
Both the mirror and manufacturer print 1.72 m2 for renal PK; the manufacturer also uses 1.73 m2 for trial exclusion. This is not an isolated mirror transcription error.
What to reconcile
Do not normalize the unusual units or infer a severe-renal regimen. Check the exact product, interactions and full labeling.
2 source identities and dates
GlobalRPh RX List - REZUROCK
GlobalRPh-hosted RX List | Source revision: 12/2024 (retained starter observation; selected sections re-read) Age 12 years and older; chronic GVHD after at least two prior systemic treatments.
Sanofi / manufacturer prescribing information | Source revision: 01/2026 Age 12 years and older; chronic GVHD after at least two prior systemic treatments.
The lower ceiling does not replace gradual initiation or interruption-related retitration.
What to reconcile
Confirm benzgalantamine strength and titration; galantamine milligram strengths are not substituted.
1 source identities and dates
GlobalRPh RX List - ZUNVEYL
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. ZUNVEYL delayed-release tablets for adult Alzheimer-type dementia. Strengths refer to benzgalantamine, not galantamine tablets.
The source permits no renal modification in severe impairment from age 12 but advises avoidance at ages 2 to less than 12. It separately excludes ESRD or hemodialysis.
What to reconcile
Check age, formulation and the full product-specific prescription. Never substitute adult renal guidance for an unestablished pediatric regimen.
1 source identities and dates
GlobalRPh RX List - Orladeyo
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Adults and children at least 2 years; capsules versus oral pellets and age-specific restrictions must be distinguished.
The selected glucose-lowering restriction and volume-depletion precautions remain product-specific.
What to reconcile
Confirm the labeled indication and renal threshold rather than applying a class assumption.
1 source identities and dates
GlobalRPh RX List - BRENZAVVY
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. BRENZAVVY oral tablets for its labeled adult type 2 diabetes indication, not an assumed class-wide CKD treatment indication.
A panel-practice exception is not unrestricted renal eligibility
The NIH panel note describes uncertain practice at CrCl 15-29; its table still says not recommended. Product-label dialysis eligibility is narrower than the abbreviated table.
What to reconcile
Confirm virologic suppression, treatment history, weight and dialysis setting with an HIV specialist. Do not silently adopt the panel minority practice as a standard regimen.
3 source identities and dates
GlobalRPh RX List - BIKTARVY
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. BIKTARVY fixed-dose HIV-1 treatment tablets. Renal eligibility depends on weight, treatment history and dialysis status, not clearance alone.
NIH ClinicalInfo HIV guidelines | Source revision: Source revision date not established in selected retrieval. Adult/adolescent antiretroviral renal dosing guidance; a panel-practice qualification is not a product-label approval.
High-flux study contradicts older nondialyzable wording
The label mirror assumes little dialysis removal. The 2018 study measured bisoprolol removal with high-flux dialysis, so the dialysis technology and evidence era matter.
What to reconcile
This small PK study does not validate a replacement dose or outcome benefit. Reconcile dialysis method, dose timing, blood pressure and pulse with the treating team; do not calculate a supplement from a clearance number.
2 source identities and dates
GlobalRPh RX List - ZEBETA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Oral bisoprolol single agent; not a bisoprolol/hydrochlorothiazide combination.
Tieu et al. 2018 - bisoprolol high-flux dialyzability
Tieu et al., Clinical Journal of the American Society of Nephrology | Source revision: 2018 Adult high-flux HD pharmacokinetic study; not a prescribing trial.
The selected evidence covers indexed eGFR 15-89, not all renal settings.
What to reconcile
Keep the below-15 and dialysis evidence gaps explicit.
1 source identities and dates
GlobalRPh RX List - BRINSUPRI
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. BRINSUPRI oral tablets. This import is limited to the renal pharmacokinetic statement; it is not a complete prescribing monograph.
The no-adjustment statement has a dialysis exclusion
The source does not recommend ESRD use during dialysis despite its broader renal statement.
What to reconcile
Keep hepatic adjustments and age/weight dosing separate; no dialysis replacement dose is inferred.
1 source identities and dates
GlobalRPh RX List - BRIVIACT
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. BRIVIACT oral tablets/solution and IV injection; age/weight-based epilepsy dosing is separate from this renal finding.
Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.